TrialBreast cancer research and treatment2016

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.

Miguel Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.